Johnson & Johnson stock falls 5.8% despite raising full-year earnings guidance

Details

Johnson & Johnson stock closed at $248.57 on October 13, 2026, down 5.8% from the previous session's close, according to market data. The move occurred in a session that saw low trading volume of only 11% of the twenty-day average. The company announced its financial results for the third quarter of 2026 on the morning of the same day, according to a filing with the U.S. Securities and Exchange Commission. Sales recorded growth of 5.9% on a reported basis, 6.0% on an operational basis (after excluding currency effects), and 6.1% on an adjusted operational basis. Diluted earnings per share (EPS) for the third quarter reached $0.09, while adjusted earnings per share reached $2.59, according to the filing. Adjusted earnings exclude non-recurring or exceptional items to provide a clearer picture of operational performance. Johnson & Johnson raised its guidance for the full year 2026, now expecting reported sales of approximately $101.2 billion (growth of 7.4% at the midpoint), and raised its adjusted earnings per share guidance by $0.06 to reach $11.10 (growth of 2.9% at the midpoint), according to the filing. The filing also noted that the company received approval from the U.S. Food and Drug Administration for its OTTAVA robotic surgical system, and approval for the drug IMAAVY as the first treatment for warm immune hemolytic anemia. Despite the positive news, the stock declined notably on the same day, which may indicate that the market was expecting stronger results or a larger guidance raise.